Tumor‐derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T‐cell‐inflamed phenotype in small cell lung cancer

Despite recent progress in subtype classification for small cell lung carcinoma (SCLC), little is known about the biomarker for triple‐negative (ASCL1, NEUROD1, and POU2F3 negative) tumors. The long‐term survival, adjuvant chemotherapy (ACT) response, and immune milieu in different SCLC subtypes hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Chaoqiang, Wang, Yue, Fu, Fangqiu, Li, Di, Zheng, Qiang, Jin, Yan, Li, Yuan, Chen, Haiquan, Zhang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542987/
https://www.ncbi.nlm.nih.gov/pubmed/37789961
http://dx.doi.org/10.1002/mco2.370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542987/
https://www.ncbi.nlm.nih.gov/pubmed/37789961
http://dx.doi.org/10.1002/mco2.370

Ejemplares similares